Your browser is no longer supported. Please, upgrade your browser.
Settings
RARE [NASD]
Ultragenyx Pharmaceutical Inc.
Index- P/E- EPS (ttm)-3.14 Insider Own1.50% Shs Outstand64.69M Perf Week2.59%
Market Cap7.80B Forward P/E- EPS next Y-4.53 Insider Trans-14.06% Shs Float63.41M Perf Month7.49%
Income-186.60M PEG- EPS next Q-1.24 Inst Own- Short Float8.51% Perf Quarter-29.40%
Sales271.00M P/S28.77 EPS this Y56.90% Inst Trans0.01% Short Ratio12.56 Perf Half Y0.88%
Book/sh17.84 P/B6.42 EPS next Y13.90% ROA-13.40% Target Price154.88 Perf Year81.45%
Cash/sh17.65 P/C6.49 EPS next 5Y17.20% ROE-23.90% 52W Range61.96 - 179.65 Perf YTD-17.27%
Dividend- P/FCF- EPS past 5Y5.00% ROI-28.70% 52W High-36.25% Beta1.89
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin97.70% 52W Low84.85% ATR6.30
Employees893 Current Ratio6.80 Sales Q/Q157.00% Oper. Margin- RSI (14)53.33 Volatility6.78% 5.10%
OptionableYes Debt/Eq0.00 EPS Q/Q77.10% Profit Margin-68.80% Rel Volume1.55 Prev Close115.71
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume429.89K Price114.53
Recom2.20 SMA205.39% SMA50-1.14% SMA2000.83% Volume664,271 Change-1.02%
May-06-21Upgrade Evercore ISI In-line → Outperform $144
May-06-21Upgrade Citigroup Neutral → Buy $160 → $151
Apr-26-21Resumed Credit Suisse Neutral $99
Mar-02-21Resumed Stifel Buy $179
Feb-12-21Downgrade JP Morgan Overweight → Neutral $165
Dec-07-20Downgrade Wedbush Outperform → Neutral $105 → $110
Nov-24-20Resumed Evercore ISI In-line $110
Nov-12-20Downgrade BofA Securities Buy → Neutral $104 → $126
Aug-02-19Resumed Wedbush Outperform $75
Mar-27-19Upgrade Morgan Stanley Equal-Weight → Overweight $68 → $83
Feb-22-19Resumed Raymond James Outperform $80
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18Upgrade Citigroup Sell → Neutral
Sep-10-18Initiated Morgan Stanley Equal-Weight $92
Jun-21-18Downgrade Credit Suisse Outperform → Neutral
May-11-18Upgrade Barclays Equal Weight → Overweight $62 → $74
May-10-18Initiated Goldman Neutral $63
Apr-18-18Upgrade SunTrust Hold → Buy
Mar-22-18Resumed Piper Jaffray Overweight $67
Feb-21-18Reiterated Stifel Buy $85 → $74
May-05-21 07:52AM  
06:01AM  
May-04-21 05:35PM  
04:01PM  
03:15PM  
Apr-28-21 04:01PM  
12:34PM  
08:31AM  
Apr-27-21 05:47PM  
Apr-22-21 08:30AM  
Apr-20-21 06:49PM  
Apr-05-21 08:00AM  
Mar-13-21 11:30AM  
Mar-09-21 01:16PM  
09:31AM  
06:35AM  
Mar-08-21 08:30AM  
Mar-04-21 02:48AM  
Mar-03-21 08:31AM  
Feb-27-21 09:23AM  
Feb-19-21 07:17AM  
Feb-17-21 04:01PM  
08:30AM  
Feb-12-21 10:09AM  
Feb-11-21 10:31PM  
05:45PM  
04:25PM  
04:05PM  
03:15PM  
Feb-04-21 08:31AM  
Jan-22-21 09:02AM  
Jan-21-21 08:30AM  
Jan-12-21 10:04AM  
Jan-11-21 07:00AM  
Jan-08-21 09:00AM  
Jan-05-21 08:31AM  
Jan-04-21 09:34AM  
Dec-28-20 06:42AM  
Dec-18-20 11:15AM  
Dec-17-20 05:25PM  
04:05PM  
04:05PM  
Dec-14-20 04:15PM  
Dec-10-20 09:40AM  
Dec-09-20 04:05PM  
Dec-05-20 01:00PM  
Nov-24-20 08:31AM  
Nov-09-20 08:05AM  
Nov-05-20 08:31AM  
Nov-02-20 11:20AM  
Oct-30-20 10:51AM  
Oct-29-20 11:02AM  
Oct-28-20 07:00PM  
03:03PM  
10:32AM  
07:47AM  
04:00AM  
Oct-27-20 05:25PM  
05:01PM  
04:59PM  
04:05PM  
Oct-26-20 04:01PM  
Oct-23-20 08:00AM  
Oct-21-20 08:31AM  
Oct-08-20 11:00AM  
Oct-07-20 05:15PM  
Oct-02-20 03:35PM  
Sep-29-20 08:57AM  
Sep-25-20 08:05AM  
Sep-03-20 08:31AM  
Sep-02-20 08:01AM  
Sep-01-20 08:31AM  
Aug-29-20 11:32AM  
Aug-27-20 05:10PM  
Aug-19-20 03:22PM  
Aug-10-20 12:43PM  
Aug-04-20 08:31AM  
Jul-31-20 01:31PM  
11:22AM  
Jul-30-20 07:00PM  
04:03PM  
Jul-24-20 08:35AM  
Jul-22-20 08:35AM  
Jul-02-20 08:41AM  
Jul-01-20 12:11PM  
07:52AM  
Jun-30-20 03:01PM  
Jun-23-20 12:20PM  
Jun-19-20 01:16PM  
10:13AM  
Jun-18-20 01:16PM  
Jun-11-20 10:21AM  
Jun-05-20 11:31AM  
May-28-20 08:30AM  
May-21-20 08:30AM  
May-15-20 08:00AM  
May-13-20 04:01PM  
May-11-20 04:02PM  
09:21AM  
May-07-20 07:13PM  
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAKKIS EMIL DPresident & CEOMay 03Sale107.8030,0003,234,0002,259,741May 05 11:32 AM
Harris ErikEVP & Chief Commercial OfficerApr 20Sale104.2839641,29527,417Apr 21 08:07 PM
Bedrosian Camille LEVP and Chief Medical OfficerApr 15Option Exercise55.005,000275,00044,139Apr 19 05:17 PM
Bedrosian Camille LEVP and Chief Medical OfficerApr 15Sale109.095,000545,45039,139Apr 19 05:17 PM
Huizenga Theodore AlanSVP, Controller and PAOMar 08Sale120.693,000362,07013,544Mar 09 12:37 PM
Harris ErikEVP & Chief Commercial OfficerMar 02Sale138.1670797,67927,813Mar 03 08:42 PM
Kassberg Thomas RichardCBO & EVPMar 01Sale138.174,572631,713107,181Mar 03 08:55 PM
Parschauer Karah HerdmanEVP and General CounselMar 01Sale138.173,970548,53530,227Mar 03 08:47 PM
Pinion John RichardSee RemarksMar 01Sale138.176,198856,37850,237Mar 03 08:48 PM
Huizenga Theodore AlanSVP, Controller and PAOMar 01Sale138.17732101,14016,544Mar 03 08:43 PM
Harris ErikEVP & Chief Commercial OfficerMar 01Sale138.172,470341,28028,520Mar 03 08:42 PM
Huang Dennis KarlEVP & Chief Tech Ops OfficerMar 01Sale138.184,255587,95640,761Mar 03 08:39 PM
Bedrosian Camille LEVP and Chief Medical OfficerMar 01Sale138.184,543627,75239,139Mar 03 08:37 PM
KAKKIS EMIL DPresident & CEOMar 01Sale141.8030,0004,254,0002,289,741Mar 03 08:36 PM
Aliski WilliamDirectorFeb 19Option Exercise97.857,500733,87573,204Feb 23 02:30 PM
Aliski WilliamDirectorFeb 19Sale149.017,5001,117,57565,704Feb 23 02:30 PM
Bedrosian Camille LEVP and Chief Medical OfficerJan 30Sale140.362,243314,82733,546Feb 02 04:28 PM
Bedrosian Camille LEVP and Chief Medical OfficerJan 15Option Exercise55.0025,0001,375,00060,789Jan 19 04:01 PM
Bedrosian Camille LEVP and Chief Medical OfficerJan 15Sale139.1825,0003,479,50035,789Jan 19 04:01 PM
Huizenga Theodore AlanSVP, Controller and PAOJan 07Option Exercise21.004,00084,00020,436Jan 08 07:05 PM
Huizenga Theodore AlanSVP, Controller and PAOJan 07Sale140.654,000562,60015,716Jan 08 07:05 PM
KAKKIS EMIL DPresident & CEOJan 04Sale136.9030,0004,107,0002,329,741Jan 05 06:45 PM
KAKKIS EMIL DPresident & CEONov 02Sale96.8230,0002,904,6002,359,741Nov 04 03:44 PM
Parschauer Karah HerdmanEVP and General CounselOct 30Option Exercise54.509,903539,71433,871Nov 02 05:05 PM
Parschauer Karah HerdmanEVP and General CounselOct 30Sale100.129,903991,48824,061Nov 02 05:05 PM
Parschauer Karah HerdmanEVP and General CounselOct 28Option Exercise54.50975,28624,065Oct 30 05:28 PM
Parschauer Karah HerdmanEVP and General CounselOct 28Sale100.00979,70023,968Oct 30 05:28 PM
Bedrosian Camille LEVP and Chief Medical OfficerOct 14Sale88.0026223,05635,789Oct 16 07:22 PM
Parschauer Karah HerdmanEVP and General CounselOct 14Sale88.0032528,60023,968Oct 16 07:21 PM
Kassberg Thomas RichardCBO & EVPOct 14Sale87.9826223,051101,478Oct 16 07:20 PM
Pinion John RichardSee RemarksOct 14Sale88.0026223,05646,299Oct 16 07:19 PM
Harris ErikEVP & Chief Commercial OfficerOct 14Sale88.0022019,36023,370Oct 16 07:20 PM
Huang Dennis KarlEVP & Chief Tech Ops OfficerOct 14Sale88.0026223,05634,699Oct 16 07:18 PM
Huizenga Theodore AlanSVP, Controller and PAOOct 14Sale87.9814612,84516,436Oct 16 07:16 PM
Sharp ShaliniEVP, FinanceOct 14Sale87.9937532,99697,812Oct 16 07:15 PM
Pinion John RichardSee RemarksOct 12Sale94.472,780262,62746,561Oct 13 05:55 PM
Parschauer Karah HerdmanEVP and General CounselOct 08Option Exercise54.5010,000545,00034,293Oct 13 05:53 PM
Parschauer Karah HerdmanEVP and General CounselOct 08Sale95.0010,000950,00024,293Oct 13 05:53 PM
Parschauer Karah HerdmanEVP and General CounselOct 06Option Exercise48.4310,000484,30034,293Oct 07 02:57 PM
Parschauer Karah HerdmanEVP and General CounselOct 06Sale90.0010,000900,00024,293Oct 07 02:57 PM
Parschauer Karah HerdmanEVP and General CounselSep 23Option Exercise48.4310,000484,30034,293Sep 24 04:47 PM
Parschauer Karah HerdmanEVP and General CounselSep 23Sale85.0010,000850,00024,293Sep 24 04:47 PM
KAKKIS EMIL DPresident & CEOSep 01Sale82.6330,0002,478,9002,389,741Sep 02 04:26 PM
Aliski WilliamDirectorAug 21Option Exercise58.745,000293,70062,018Aug 25 03:56 PM
Aliski WilliamDirectorAug 21Sale86.575,000432,85057,018Aug 25 03:56 PM
Parschauer Karah HerdmanEVP and General CounselAug 17Option Exercise54.5010,000545,00036,663Aug 19 02:12 PM
Sharp ShaliniCFO & Executive Vice PresidentAug 17Option Exercise61.5111,357698,524105,375Aug 19 02:11 PM
Parschauer Karah HerdmanEVP and General CounselAug 17Sale88.4312,3701,093,88424,293Aug 19 02:12 PM
Sharp ShaliniCFO & Executive Vice PresidentAug 17Sale88.4014,3781,271,07398,187Aug 19 02:11 PM
SIEGALL CLAY BDirectorAug 10Option Exercise40.371,59664,4314,146Aug 11 12:21 PM
SIEGALL CLAY BDirectorAug 10Sale85.0111,346964,5232,550Aug 11 12:21 PM
SIEGALL CLAY BDirectorAug 07Option Exercise25.8923,404605,84435,704Aug 11 12:21 PM
SIEGALL CLAY BDirectorAug 07Sale85.5523,4042,002,21212,300Aug 11 12:21 PM
KAKKIS EMIL DPresident & CEOJul 13Sale85.3540,0003,414,0002,419,741Jul 15 01:22 PM
Huizenga Theodore AlanSVP, Controller and PAOJul 08Option Exercise21.002,00042,00018,582Jul 10 05:21 PM
Huizenga Theodore AlanSVP, Controller and PAOJul 08Sale91.002,638240,05816,582Jul 10 05:21 PM
Fust Matthew KDirectorJul 06Option Exercise21.006,181129,80119,731Jul 08 12:30 PM
Fust Matthew KDirectorJul 06Sale90.006,181556,29013,550Jul 08 12:30 PM
Huizenga Theodore AlanSVP, Controller and PAOJul 01Option Exercise21.001,50031,50018,720Jul 06 02:21 PM
Fust Matthew KDirectorJul 01Option Exercise21.005,000105,00018,550Jul 06 02:21 PM
Huizenga Theodore AlanSVP, Controller and PAOJul 01Sale81.002,611211,49117,220Jul 06 02:21 PM
Fust Matthew KDirectorJul 01Sale85.005,000425,00013,550Jul 06 02:21 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 04Option Exercise48.432,564124,175103,772Jun 05 04:59 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 04Sale74.012,564189,762101,208Jun 05 04:59 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 03Option Exercise48.4310,234495,633111,442Jun 05 04:59 PM
Harris ErikEVP & Chief Commercial OfficerJun 03Sale74.692,516187,92020,854Feb 03 08:04 PM
Sharp ShaliniCFO & Executive Vice PresidentJun 03Sale74.2310,234759,670101,208Jun 05 04:59 PM
Huizenga Theodore AlanSVP, Controller and PAOMay 26Sale74.9326019,48218,331May 27 03:14 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 19Option Exercise60.577,128431,710104,851May 20 07:49 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 19Sale73.327,128522,625100,944May 20 07:49 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 18Option Exercise70.5719,5931,382,678122,929May 20 07:49 PM
Aliski WilliamDirectorMay 18Option Exercise40.377,500302,77555,424May 20 07:50 PM
Aliski WilliamDirectorMay 18Sale74.657,500559,87547,924May 20 07:50 PM
Sharp ShaliniCFO & Executive Vice PresidentMay 18Sale73.3321,9851,612,260100,944May 20 07:49 PM
Aliski WilliamDirectorMay 18Sale74.0220,0001,480,32270,350Jun 03 04:26 PM
Fust Matthew KDirectorMay 18Sale75.001,875140,62511,000May 19 07:13 PM
Parschauer Karah HerdmanEVP and General CounselMay 18Sale74.722,722203,37427,312May 19 07:12 PM
Huizenga Theodore AlanSVP, Controller and PAOMay 15Option Exercise21.001,50031,50020,219May 19 07:15 PM
Huizenga Theodore AlanSVP, Controller and PAOMay 15Sale71.002,461174,73118,719May 19 07:15 PM